6,250 Ebola cases and 3,039 deaths have been recorded since mid-May, pushing Congo to shift toward a village-centered response as Africa CDC says the outbreak likely has not yet peaked.
63% of deaths in the past week occurred outside treatment centers, underscoring weak community surveillance and trust gaps in eastern Congo, where insecurity, displacement and heavy population movement are accelerating spread.
19% of an estimated 97,600 expected contacts from cases confirmed in the last three weeks have been traced, even though officials say 81% of listed contacts were followed up.
1,300 treatment beds were available in late August, with 869 patients occupying them, but WHO and frontline workers say centers in Ituri are saturated, referral options in North Kivu are limited and staff are exhausted.
Burial practices remain another weak point, with teams attacked in some areas and mourners gathering close to coffins, highlighting how conflict and distrust are still hampering containment.
Could the rebel conflicts fueling Congo's Ebola crisis force a permanent, global redesign of how we handle epidemics in war zones?
With no vaccine for the Bundibugyo strain, can a radical village-led strategy stop Congo's expanding outbreak before it crosses borders?
As health workers face deadly attacks, will transparent coffins and local mediators be enough to rebuild trust and halt the virus?
The 2026 Bundibugyo Ebola Outbreak in DRC: Record Deaths, Scientific Hurdles, and the Rise of Village-Centered Response
Overview
The 2026 Bundibugyo Ebola outbreak in the DRC became the deadliest in the country’s history, driven by a new virus variant with no approved vaccine or treatment. Health authorities faced major challenges: insecurity and attacks on clinics disrupted surveillance, while deep community distrust made centralized responses ineffective. As a result, organizations shifted to a village-centered strategy, empowering local leaders to deliver accurate health messages and reduce stigma. Meanwhile, the virus’s genetic mutations complicated diagnosis, and many patients showed only mild symptoms, allowing silent spread. Global efforts accelerated vaccine trials, but weakened health systems and funding cuts made containment even harder.